Sign In
2 Steps
Maximum: 1 CME cr.
Sign in to view your progression
Program overview
Educational goals
Target audience
Credit designation
Disclosures

Topic description:
This Module presents the epidemiology, prevalence, classification systems, and models for female sexual disorders. The historical development of sexual disorders in the DSM and the changes in definitions in the transition from DSM IV-TR to DSM 5, as well as new ISSWSH, endorsed nomenclature are also discussed.  Lastly, foundational knowledge on the neurobiology related to female sexual function and dysfunction and its importance to clinical practice is presented.

Video segments in the learning module:
- Video 1: Female Sexual Dysfunction Nomenclature
- Video 2: Models of Female Sexual Function
- Video 3: Evolution of Female Sexual Function Diagnoses
- Video 4: Neurophysiological Considerations for the Clinical Evaluation and Management of Female Sexual Dysfunction

Faculty Information
Stanley E. Althof, PhD
Executive Director, Center for Marital and Sexual Health of South Florida
West Palm Beach, Florida
Professor Emeritus, Case Western Reserve University School of Medicine
Cleveland, Ohio

Anita H. Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor of Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Sharon J. Parish, MD
Professor of Medicine in Clinical Psychiatry and Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York

Best practice:
Health Care Providers (HCPs) caring for women with sexual health concerns understand and apply knowledge of the prevalence and classification of sexual disorders to their clinical approach. Models for understanding the development and evolution of sexual problems aid HCPs in optimal diagnosis and management.

Current practice:
Practitioners are inadequately educated about the prevalence of sexual dysfunctions and schema on which to base the evaluation of these problems in clinical settings.

Resulting gaps:
Providers inadequately screen and evaluate women for sexual problems across all age groups and practice settings.

Outcome indicated/Improvement in:
Providers will be educated about the prevalence and classification of sexual disorders and improve their detection and evaluation of these problems in an array of clinical settings.

Learning objectives:
(1) Understand the broad epidemiology, prevalence, classification systems, and models for female sexual disorders in clinical practice.
(2) Identify changes in definitions in the transition from DSM IV-TR to DSM 5 as well as new ISSWSH endorsed nomenclature.

Medical health care practitioners (MDs, DOs, PAs, NPs, etc.) in any field (Sexual Medicine, Obstetrics & Gynecology, Internal Medicine, Family Medicine, Urology, etc.) who would like to address sexual health in caring for their female patients.

ISSWSH Learner Notification

Module 1: Female Sexual Dysfunction Nomenclature and Epidemiology
Dr. S. Althof, Dr. A. Clayton and Dr. S. Parish

January 1, 2019 – January 1, 2021
Online

Acknowledgment of Financial Commercial Support
Valeant Pharmaceuticals North America LLC

Acknowledgment of In-Kind Commercial Support (Only for ACCME, ANCC and ACPE)
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the self-assessment questionnaire with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society for the Study of Women’s Sexual Health (ISSWSH). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this internet activity enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives - After attending this program you should be able to:

  1. Understand the broad epidemiology, prevalence, classification systems and models for female sexual disorders in clinical practice
  2. Identify changes in definitions in the transition from DSM IV-TR to DSM 5

The following disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.

All of these relationships were treated as a conflict of interest and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.

First

Last

Commercial Interest

S.

Althof

AMAG/Palatin: Scientific/Medical Advisory Board Member,
Clinical Outcomes Solutions: Research Grant Site Principal Investigator, Endoceutics: Research Grant Site Principal Investigator,
ForHims: Scientific/Medical Advisory Board Member,
Ixchelsis: Research Grant Overall Principal Investigator,
Strategic Science Technology: Research Grant Site Principal Investigator

AH

Clayton

Changes in Sexual Functioning Questionnaire, Guilford Publications, Ballantine Books/Random House: Patent Holder,
Axsome, Endoceutics, Inc., Janssen, Palatin Technologies, Sage Therapeutics, Takeda: Research Grant Site Principal Investigator,
Euthymics and S1 Biopharma: Stock Shareholder,
Alkermes, AMAG Pharmaceuticals, Inc., Ivix, Palatin Technologies, S1 Biopharma, Sage Therapeutics, Sprout Pharmaceuticals, Takeda: Consultant

S.

Parish

Duchesnay pharmaceuticals: Scientific/Medical Advisory Board Member,
Allergen: Scientific/Medical Advisory Board Member,
AMAG: Consultant
Proctor and Gamble: Consultant

Female Sexual Dysfunction Nomenclature and Epidemiology
Final assessment & Certificate

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies